Botox specials advertising rules turn on one fact most promotion advice never mentions: BOTOX Cosmetic's labeling carries a boxed warning, and under 21 CFR 202.1 a boxed warning closes the reminder advertisement route that ordinary price promotions rely on. What is left is a narrow price-only exemption with a strict condition attached.
This is the promotion nearly every med spa runs, usually as a per-unit price in the week before a holiday. It is also the one with the least room to move, and the reason is structural. Educational, not legal advice, and current as of October 2026.
Every drug ad is one of two things
Federal drug advertising law sorts a prescription drug ad into two shapes. A product-claim ad says something about the drug, so it has to carry the brand name, the established name of each active ingredient, and a brief summary covering side effects, contraindications and effectiveness, in fair balance with the benefit claims. A reminder ad says nothing about the drug at all.
The reminder category is the one built for promotions. Under 21 CFR 202.1 a reminder advertisement calls attention to the name of the drug product without including indications or dosage recommendations, and may add limited extras: the company name, the dosage form, the price. That shape is exactly what a price special wants to be, which is why it matters that the door is shut.
The boxed warning closes the reminder route
BOTOX Cosmetic's FDA-approved prescribing information opens with a boxed warning on distant spread of toxin effect, which states that the effects of the product and all botulinum toxin products may spread from the injection area to produce symptoms consistent with botulinum toxin effects. That warning is what removes the reminder-ad option.
21 CFR 202.1 says reminder advertisements, other than those solely intended to convey price information, "are not permitted for a prescription drug product whose labeling contains a boxed warning relating to a serious hazard associated with the use of the drug product". A boxed-warning drug gets no reminder ad except a price one.
So the familiar advice to simply drop the claims and post the brand name with a number is not a safe harbour here. It lands the ad in the one reminder subcategory that survives, and that subcategory has a condition the per-unit teaser price almost never satisfies.
The price exemption requires an all-in price
The surviving route is 21 CFR 200.200, which exempts price-information reminder ads on two conditions. The only purpose must be to tell consumers the price charged for a prescription, with no representation or suggestion about the product's safety, effectiveness or indications. And the stated price must include all charges to the consumer.
The section names the components: the cost of the drug product, professional fees, and handling fees where there are any. Mailing and delivery fees may be stated separately and without repetition. Nothing in it contemplates a headline number that the consumer then has to add things to.
Measure the usual med spa special against that. A per-unit price quoted without the injector fee, a price that only applies above a minimum unit count, and a price good only with a membership all state a number that is not the whole charge. The structure of the promotion, not the wording, is what fails.
| Ad shape | What it may say about the drug | What it has to carry | Available for a boxed-warning drug |
|---|---|---|---|
| Product-claim ad | Indications, benefits, dosage, anything substantive | Brand name, established name of each active ingredient, and a brief summary of side effects, contraindications and effectiveness in fair balance | Yes, with the full disclosure |
| Reminder ad | Nothing: the name, and limited extras such as dosage form or price | Proprietary name and the established name of each active ingredient | No, under 21 CFR 202.1 |
| Price-only reminder ad | Nothing beyond the price charged | A price including all charges to the consumer: drug product, professional fees and handling fees | Yes, on the 21 CFR 200.200 conditions |
| A typical per-unit special | Usually a benefit line, a holiday hook, or a result | Both of the above at once, which is the conflict | Not as commonly written |
Who these rules bind, and what binds the practice
Here is the part the compliance posts skip. The federal drug advertising rules are written for firms: manufacturers, packers and distributors of a prescription drug who advertise it, and, in the regulation's own framing, all persons they cause to issue an advertisement for it. A med spa advertising its own service is not automatically one of those firms.
That distinction cuts both ways, and the second way is the one worth planning around. A practice running manufacturer-supplied creative, a co-branded promotion, or a loyalty program tied to the brand is much closer to the persons-caused-to-issue language than a practice writing its own copy. Read the brand agreement before assuming the category question is settled.
What binds the practice directly is a different stack. The FTC's health products compliance guidance sets two principles: advertising must be truthful and not misleading, and an advertiser must have adequate substantiation for objective claims before dissemination, which for health benefits generally means competent and reliable scientific evidence. North Carolina adds its medical board.
NC Medical Board Position Statement 8.3.1 on advertising and publicity, adopted November 1999 and amended July 2021, treats deceptive, false or misleading advertising as unprofessional conduct under the Medical Practice Act. Among its stated principles: ads should not omit material facts, and licensees should be prepared to substantiate what they claim. Omitting material facts is where an incomplete price sits.
The platform is a fourth rulebook, and the strictest in practice
Before any of the above is tested, the ad has to clear the platform. Meta's advertising standards for drugs and pharmaceuticals require that advertisers promoting prescription drugs be actively certified with LegitScript or have gone through Meta's internal review, obtain authorization from Meta, target only eligible countries, and target only people 18 or older, as of October 2026.
Meta names online pharmacies, telehealth providers and pharmaceutical manufacturers as the advertiser types it certifies, and the policy does not mention med spas, so whether a practice promoting a named injectable is treated as a prescription-drug advertiser is an application question rather than a settled one.
What this looks like when it runs
HIPAA compliance across digital forms, CRM automations and ad landing pages is the buyer criterion a promotion actually runs on, and the working version is a set of plumbing decisions made before the campaign: patient information stays out of ad platforms and pixels, form submissions land in a system the practice owns, and treatment-level pages carry no retargeting tags.
Mirastart builds that layer. Booking systems that calculate genuine availability and send confirmations automatically, follow-up automation that chases what people forget, and reporting that counts booked chairs rather than clicks all run in production for Charlotte businesses today. For a promotion, the useful piece is a landing page that states the all-in price once and a booking flow that applies it, so the offer the ad names is the offer the calendar honours.
On privacy the controls are worth checking on any agency, ours included, and we sign a business associate agreement where an engagement touches protected health information. The practice stays the covered entity.
Sources
- 21 CFR 202.1 - Prescription-drug advertisements (Electronic Code of Federal Regulations) - Defines a reminder advertisement (the name of the drug product, without indications or dosage recommendations, plus limited extras such as dosage form or price) and states that reminder advertisements, other than those solely intended to convey price information, are not permitted for a prescription drug product whose labeling contains a boxed warning relating to a serious hazard. Also the source of the product-claim requirements: established name of each active ingredient, and a brief summary of side effects, contraindications and effectiveness in fair balance. The section is addressed to manufacturers, packers and distributors who advertise a prescription drug, and to the persons they cause to issue an advertisement.
- 21 CFR 200.200 - Prescription drugs; reminder advertisements and reminder labeling to provide price information to consumers - The price-only exemption and its two conditions: the only purpose is to provide consumers with the price charged for a prescription, with no representation or suggestion about safety, effectiveness or indications for use; and the stated price must include all charges to the consumer, including the cost of the drug product, professional fees and handling fees. Mailing and delivery fees may be stated separately and without repetition.
- BOTOX Cosmetic (onabotulinumtoxinA) prescribing information (U.S. Food and Drug Administration) - FDA-approved labeling carrying the boxed warning on distant spread of toxin effect: effects may spread from the area of injection to produce symptoms consistent with botulinum toxin effects, reported hours to weeks after injection. The existence of a boxed warning in the labeling is the fact that triggers the 21 CFR 202.1 reminder-advertisement restriction. The labeling also notes no definitive serious adverse event reports of distant spread at the labeled doses for dermatologic use.
- NCMB Position Statement 8.3.1: Advertising and Publicity (North Carolina Medical Board) - Adopted November 1999, amended July 2021. Deceptive, false or misleading advertising constitutes unprofessional conduct under the Medical Practice Act; advertisements should not contain false claims or misrepresentations of fact expressly or by implication, should not omit material facts, and licensees should be prepared to substantiate claims. The test is whether a member of the general public would be confused or deceived. A position statement, not a statute or rule.
- Health Products Compliance Guidance (Federal Trade Commission) - The FTC's two principles: advertising must be truthful and not misleading, and advertisers must have adequate substantiation for objective claims before dissemination, generally competent and reliable scientific evidence for health benefits. Also states that attempts to disclaim dramatic results with wording such as results not typical do not cure the deception. Business guidance issued December 2022; it does not have the force or effect of law and does not mention med spas or injectables by name.
- Drugs and Pharmaceuticals - Meta Advertising Standards - Advertisers promoting prescription drugs must be actively certified with LegitScript or have completed Meta's internal review, obtain authorization from Meta, target only eligible countries (United States, Canada or New Zealand) and target only people 18 or older. Meta names online pharmacies, telehealth providers and pharmaceutical manufacturers as the advertiser types it certifies; the policy does not mention med spas, so its application to a practice promoting a named injectable is not settled on the face of the policy.